Your browser doesn't support javascript.
loading
Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.
Thibouw, David; Truc, Gilles; Bertaut, Aurélie; Chevalier, Cédric; Aubignac, Léone; Mirjolet, Céline.
Afiliação
  • Thibouw D; Department of Radiation Oncology, Georges François Leclerc Cancer Center, Dijon, France.
  • Truc G; Department of Radiation Oncology, Georges François Leclerc Cancer Center, Dijon, France. gtruc@cgfl.fr.
  • Bertaut A; Department of Statistics, Georges François Leclerc Cancer Center, Dijon, France.
  • Chevalier C; Department of Radiation Oncology, Georges François Leclerc Cancer Center, Dijon, France.
  • Aubignac L; Department of Medical Physics, Georges François Leclerc Cancer Center, Dijon, France.
  • Mirjolet C; Department of Radiation Oncology, Georges François Leclerc Cancer Center, Dijon, France.
J Neurooncol ; 137(2): 429-438, 2018 Apr.
Article em En | MEDLINE | ID: mdl-29374810
BACKGROUND AND PURPOSE: We aimed to compare three-dimensional conformal radiotherapy (3D-CRT) with intensity-modulated radiotherapy (IMRT) for the treatment of glioblastoma. MATERIALS AND METHODS: Retrospective study of 220 patients with glioblastoma, treated with 3D-CRT or IMRT, with or without surgery. Dosimetric parameters as well as clinical and survival data for the two techniques were analyzed and compared. RESULTS: The median conformity index was 1.53 (range 0-2.69) for 3D-CRT and 1.25 (range 0.97-2.01) for IMRT, p < 10-4. The median homogeneity index was 0.10 (range 0.03-0.32) for 3D-CRT and 0.07 (range 0.03-0.18) for IMRT, p < 10-4. There were significantly fewer acute grade 1 and 2 neurological toxicities in the IMRT group especially for edema (1.3 versus 12.4%, p = 0.017), concentration disorders (6.6 versus 19.9%, p = 0.003) and consciousness disorders (2.6 versus 13.2%, p = 0.002) although IMRT patients had a significantly worse pre-treatment neurological status than 3D-CRT patients. Median survival was 16.0 months (range 11.9-17.8) for IMRT and 13.4 months (range 11.7-15.7) for 3D-CRT patients (p = 0.542). CONCLUSION: IMRT improved target conformity and reduced neurological toxicities for patients with glioblastomas.
Assuntos
Palavras-chave

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Radioterapia Conformacional / Radioterapia de Intensidade Modulada Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Radioterapia Conformacional / Radioterapia de Intensidade Modulada Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article